Hemab Therapeutics Holdings, Inc. (COAG) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.44B USD. 52-week range 23.00 to 55.42 USD. Data as of 2026-10-09.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and ...